OOIR: Observatory of International Research

Papers

(The TQCC of Hepatology Communications is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Hsa_circ_0109623 regulates the progression of autoimmune liver disease through Hsa_miR_146b-3p/Sortilin 1–mediated activation of CD4+ T cells	210
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores	155
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	133
Unraveling enhanced liver regeneration in ALPPS: Integrating multi-omics profiling and in vivo CRISPR in mouse models	100
Assessing the risk of surgery in patients with cirrhosis	86
GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond	84
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	84
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	76
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	67
Comparison of clinical outcomes in patients with refractory ascites treated with either TIPS, tunneled peritoneal catheter, or ascites pump	64
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	63
	58
Presence of pseudo-Kayser-Fleischer rings in patients without Wilson disease: a prospective cohort study	56
Poor emotional well-being and energy are associated with mortality in patients with advanced liver failure	56
	53
	53
	52
	52
In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology	51
Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care	51
Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol-Associated Liver Disease	51
Optimal alpha-1 antitrypsin level cutoffs for genotype identification in patients with chronic liver disease	49
Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition	48
Crosstalk of lysyl oxidase-like 1 and lysyl oxidase prolongs their half-lives and regulates liver fibrosis through Notch signal	46
Mandatory Hepatology Education for Internal Medicine Residents: Long‐Term Effects and Implications for Workforce Needs	46

Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis	46
Berberine alleviates concanavalin A–induced autoimmune hepatitis in mice by modulating the gut microbiota	44
Pneumosepsis survival in the setting of obesity leads to persistent steatohepatitis and metabolic dysfunction	42
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	42
Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA‐2B Score Among US Adults	41
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	41
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	41
Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations	41
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	39
Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease	38
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging	38
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	38
Serum amyloid P (PTX2) attenuates hepatic fibrosis in mice by inhibiting the activation of fibrocytes and HSCs	37
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis	36
Hepatic MCPIP1 protein levels are reduced in NAFLD patients and are predominantly expressed in cholangiocytes and liver endothelium	35
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials	35
Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma	34
Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria	34
Inhibition of lysyl oxidase‐like 2 overcomes adhesion‐dependent drug resistance in the collagen‐enriched liver cancer microenvironment	34
Bile acids promote the development of HCC by activating the inflammasome	33
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	33
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	33
A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis	33
Association between widespread pain and associated symptoms in patients with cirrhosis	32
Homeopathic remedies and liver injury: Authors’ reply to central council for research in homeopathy	32
Visualizing in situ viral replication across the natural history of chronic HBV infection	32
The prevalence and risk factors for cognitive impairment in obesity and NAFLD	32
Overexpression of NgBR inhibits high-fat diet–induced atherosclerosis in ApoE-deficiency mice	32
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort	31
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	31
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	31
Cellular origin and molecular mechanisms of lung metastases in patients with aggressive hepatoblastoma	31
The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort study	31
Protective role of 17β-estradiol in alcohol-associated liver fibrosis is mediated by suppression of integrin signaling	30
Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis	29
A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis	29
The roles of nuclear receptors in cholesterol metabolism and reverse cholesterol transport in nonalcoholic fatty liver disease	29
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	29
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis	29
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	28
Development and evaluation of a virtual reality driving test for patients with cirrhosis	28
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	28
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	27
Reply : Understanding survival comparisons in non-randomized treatment comparisons for patients with early-stage HCC	27
Erratum: CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression	27
Management and outcomes after liver transplantation for progressive familial intrahepatic cholestasis: A systematic review and meta-analysis	27
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	26
Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis	26
MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort	26
Understanding survival comparisons in nonrandomized treatment comparisons for patients with early-stage HCC	26

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	25
The health care experience of adults with metabolic dysfunction–associated steatohepatitis and influence of PNPLA3: A qualitative study	25
Subjective and objective burden on providers from a multicenter app-based study of patients with cirrhosis and caregivers	24
Comparison of blood-based liver fibrosis scores in the Mount Sinai Health System, MASLD Registry, and NHANES 2017–2020 study	24
Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease	24
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	24
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	24
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	24
Validation of MELD3.0 in 2 centers from different continents	24
Development and validation of a biomarker index for HCC treatment response	23
Taurine-conjugated bile acids and their link to hepatic S1PR2 play a significant role in hepatitis C–related liver disease	23
The mechanistic insights behind the anticancer effects of statins in liver cancer	23
Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus	22
Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma	22
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis	22
Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review	22
Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice	22
Issue Information	22
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1	22
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	22
Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study	22
Is Hepatocyte Necrosis a Good Marker of Donor Liver Viability During Machine Perfusion?	22
An RNA Interference/Adeno‐Associated Virus Vector–Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus	21
Comment on “Heterologous adenovirus‐vector/messenger RNA regimen, humoral response and liver transplant recipients”	21
Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma	21
Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases	21
Direct Conversion of Human Endothelial Cells Into Liver Cancer‐Forming Cells Using Nonintegrative Episomal Vectors	21
Issue Information	21
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	21
Fatty Liver and the Coronavirus Disease 2019 Pandemic: Health Behaviors, Social Factors, and Telemedicine Satisfaction in Vulnerable Populations	20
Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States	20
Sphingosine kinase 2 (SphK2) depletion alters redox metabolism and enhances inflammation in a diet-induced MASH mouse model	20
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort	20
A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High‐Risk Primary Sclerosing Cholangitis	20
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	20
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	20
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	19
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	19
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	19
Tinospora cordifolia‐associated hepatotoxicity has been scientifically misconstrued, in haste	19
Circulating cell-free messenger RNA secretome characterization of primary sclerosing cholangitis	19
Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation	19
High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module	19
The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBC	19
A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway	19
Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C	18
Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach	18
Clinical phenotype of adult‐onset liver disease in patients with variants in ABCB4 , ABCB11 , and ATP8B1	18
Child hepatitis of unknown origin may be due to insufficient understanding of adenovirus pathogenicity	18
The emotional burden of caregiving for patients with cirrhosis	18
β‐catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma	18
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action	18
Substance‐use simulation impairs driving capability in patients with cirrhosis regardless of hepatic encephalopathy	18
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	18
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	18
Ablation of high‐mobility group box‐1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling‐deficient mice	18
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767	18
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	17
Patterns of kidney dysfunction in acute‐on‐chronic liver failure: Relationship with kidney and patients’ outcome	17
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	17
Pregnancy and liver-related outcomes after alcohol-associated hepatitis: A global multicenter study	17
Aging aggravates liver fibrosis through downregulated hepatocyte SIRT1-induced liver sinusoidal endothelial cell dysfunction	17
Reply: Is nesting addiction medicine and hepatology care in the outpatient setting worthwhile? A retrospective case series at a single tertiary center	17
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	17
Mitochondrial quality control in alcohol-associated liver disease	17
Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact	16
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	16
A randomized study of ceftriaxone for the prevention of infections in hospitalized patients with advanced cirrhosis	16
A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis	16
Preoperative portal vein recanalization–transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation	16
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application	16
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	16
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	16
Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV	16
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	16
FAK inhibition delays liver repair after acetaminophen-induced acute liver injury by suppressing hepatocyte proliferation and macrophage recruitment	16
PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18	15
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	15
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population	15
In utero exposure to antihistamines and risk of hepatocellular carcinoma in a multigenerational cohort	15

Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex	15
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant	15
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B	15
What will it take to cure hepatitis B?	15
Neurogastroenterology and motility disorders in patients with cirrhosis	14
Iron overload disorders	14
Molecular networks of hepatoblastoma predisposition and oncogenesis in Beckwith‐Wiedemann syndrome	14
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study	14
Complementary and alternative medicines and liver disease	14
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?	14
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	14
Depression and anxiety management in cirrhosis	14
A versatile method to profile hepatitis B virus DNA integration	14
Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD	14
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study	14
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement	14
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus	14
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study	14
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists	14
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	14
Meta‐analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions	14
Malassezia restricta promotes alcohol-induced liver injury	14
Wilson disease: a summary of the updated AASLD Practice Guidance	14
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD	14
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	14
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH	13
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	13
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma	13
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis	13
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD	13
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	13
PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis	13
Higher ultra-processed food intake was positively associated with odds of NAFLD in both US adolescents and adults: A national survey	13
Identification of hepatic steatosis in living liver donors by machine learning models	13
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	13
Setting up criteria for drug‐induced autoimmune‐like hepatitis through a systematic analysis of published reports	13
Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program	13
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	13
Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model	13
Neutrophil extracellular traps induce intrahepatic thrombotic tendency and liver damage in cholestatic liver disease	13
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	13
Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans	13
Regional changes in intestinal permeability in cirrhosis are associated with mucosal bacteria	13
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	13
Brief alcohol interventions are underutilized in persons with nonalcohol-associated chronic liver diseases	13
Granulomatous liver diseases	13
Liver organoids: established tools for disease modeling and drug development	12
A novel point-of-care test for cirrhosis based on dimeric to monomeric IgA ratio in blood: a pilot cohort study	12
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	12
Cured HCV patients with suboptimal hepatitis B vaccine response exhibit high self-reactive immune signatures	12
Addressing racial and ethnic disparities in US liver cancer care	12
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	12
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	12
Time trends in mortality and life expectancy in 22,658 patients hospitalized with alcohol-associated cirrhosis: A nationwide cohort study	12
Humoral and T-cell–mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients	12
Homeopathic formulations and liver injury: Authors’ reply to national homoeopathy research institute in mental health	12
All perspectives need to be accounted for when determining the effectiveness of therapies for alcohol use disorder	12
Overexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer	12
Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele	12
Adipokines regulate the development and progression of MASLD through organellar oxidative stress	12
Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis	12
Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis	12
Erratum: Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): A nationwide cohort study	12
Dysregulation of lipid metabolism in the pseudolobule promotes region-specific autophagy in hepatitis B liver cirrhosis	12
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	12
Cost and value in liver disease guidelines: 2011–2022	12
mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes	11
Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study	11
Erratum: Improved outcomes after hypothermic oxygenated machine perfusion in liver transplantation-Long-term follow-up of a multicenter randomized controlled trial	11
National Liver Cancer Screening Trial (TRACER) study protocol	11
Palliative care experience and perceived gaps in training among transplant hepatology fellows: A national survey	11
Gastroenterology and hepatology journals should increase women authorship representation: Room for improvement in trends from 2017 to 2024	11
Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: Evidence from prospective cohort studies	11
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	11
Circulating bacterial peptides and linked metabolomic signatures are indicative of early mortality in pediatric cirrhosis	11
Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial	11
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model	11
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	11
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus	11
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort	11
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	11
Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol	11
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	11
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	11
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	11
Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis	11
Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC	11
Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring	11
Identification of immunogenic HLA-A*02:01 epitopes associated with HCC for immunotherapy development	11
Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis	11
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	11
	11
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”	10
Biological and clinical role of TREM2 in liver diseases	10
Availability of a Web and Smartphone Application to Stratify the Risk of of Early Allograft Failure Requiring Liver Retransplantation	10